Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha.
Newton
R C
RC
Departments of Inflammatory Diseases Research and Chemical and Physical Sciences, The DuPont Pharmaceuticals Company, Experimental Station, P.O. Box 80500, Wilmington, Delaware 19880-0500, USA.
Decicco
C P
CP
D000818:Animals; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D000242:Cyclic AMP / Q000096:biosynthesis; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000627:therapeutic use; D005786:Gene Expression Regulation; D006801:Humans; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D018124:Receptors, Tumor Necrosis Factor / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism
D004791:Enzyme Inhibitors; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000242:Cyclic AMP; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D008666:Metalloendopeptidases